This article is more than 5 years old. Information may no longer be current.
Industry partnership expands access to blood test for colorectal cancer
Click Here to Manage Email Alerts
Applied Proteomics, a company that develops proteome-based blood tests for early detection and monitoring of diseases, has partnered with health care cost management solutions provider MultiPlan, thus expanding access to the company’s colorectal cancer blood test to 50 to 75 million people in the MultiPlan network.
The SimpliPro Colon test is “a blood-based test that assesses the risk for colorectal cancer and advanced adenoma in elevated risk patients,” and is the first product resulting from the company’s proprietary protein discovery and test delivery platform, called “Linus,” to be commercialized. The test has been in use in the U.S. since launching in December 2015, according to a press release.
“Signing this agreement with MultiPlan further validates that Linus can power commercial applications that benefit the patient and reduce the cost to the overall health care system,” Premal Shah, PhD, CEO of Applied Proteomics, said in the press release. “This agreement increases patient access to utilize the SimpliPro Colon test, and will help save lives by aiding in detecting colorectal cancer earlier for patients that refuse or have been delaying colonoscopy, the standard of care.”
Clinical data on the SimpliPro Colon test was presented last year at DDW 2016, and showed the test detected all stages of colorectal cancer with 81% sensitivity and 78% specificity.
Reference:
Wilcox BE, et al. Abstract #862. Presented at: Digestive Disease Week; May 21-24, 2016; San Diego.
Disclosures: Shah is employed by Applied Proteomics.